Literature DB >> 7837236

(+)-cis-4,5,7a,8,9,10,11,11a-octahydro-7H-10-methylindolo[1,7- bc][2,6]-naphthyridine: a 5-HT2C/2B receptor antagonist with low 5-HT2A receptor affinity.

J Nozulak1, H O Kalkman, P Floersheim, D Hoyer, P Schoeffter, H R Buerki.   

Abstract

The indolonaphthyridine 8 is described as a selective 5-HT2C/2B vs 5-HT2A receptor antagonist. The compound was synthesized in seven steps starting from indoline and isonicotinic acid chloride. The key step is a photocyclization of the indolinyl tetrahydropyridinocarbamic acid ethyl ester 4 to the cis-octahydroindolo[1, 7-bc][2,6]naphthyridinecarbamic acid ethyl ester 5. The synthesis was accomplished by reduction with aluminum hydride and racemic resolution. The indolonaphthyridine 8 exerted the binding profile of a selective 5-HT2C receptor ligand (pKD 7.8) and behaved as an antagonist on the 5-HT-induced accumulation of inositol phosphates in pig choroid plexus cells (pKB 7.13). Compound 8 dose-dependently inhibited the ACTH response to MK-212 in rats and the MK-212-induced hypophagic effect with an ID50 value of 0.3 mg/kg sc. Compound 8 acted as a 5-HT2B receptor antagonist at the rat stomach fundus with a pKB value of 7.34.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7837236     DOI: 10.1021/jm00001a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Characterization of the 5-hydroxytryptamine receptors mediating contraction in the pig isolated intravesical ureter.

Authors:  Medardo Hernández; María Victoria Barahona; Ulf Simonsen; Paz Recio; Luis Rivera; Ana Cristina Martínez; Albino García-Sacristán; Luis M Orensanz; Dolores Prieto
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

2.  Opposing effects of 5-HT(2A) and 5-HT(2C) receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test.

Authors:  Paul J Fletcher; Maria Tampakeras; Judy Sinyard; Guy A Higgins
Journal:  Psychopharmacology (Berl)       Date:  2007-08-03       Impact factor: 4.530

Review 3.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

4.  RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist.

Authors:  D W Bonhaus; L A Flippin; R J Greenhouse; S Jaime; C Rocha; M Dawson; K Van Natta; L K Chang; T Pulido-Rios; A Webber; E Leung; R M Eglen; G R Martin
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 5.  Cardiovascular effects of antiobesity drugs: are the new medicines all the same?

Authors:  Mauro Cataldi; Angelo Cignarelli; Francesco Giallauria; Giovanna Muscogiuri; Luigi Barrea; Silvia Savastano; Annamaria Colao
Journal:  Int J Obes Suppl       Date:  2020-07-20

6.  Serotonergic/glutamatergic interactions: potentiation of phencyclidine-induced stimulus control by citalopram.

Authors:  J C Winter; J R Eckler; K C Rice; R A Rabin
Journal:  Pharmacol Biochem Behav       Date:  2005-07       Impact factor: 3.533

7.  Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the discriminative stimulus effects of cocaine in rats.

Authors:  Malgorzata Filip; Marcy J Bubar; Kathryn A Cunningham
Journal:  Psychopharmacology (Berl)       Date:  2005-10-28       Impact factor: 4.530

8.  Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy.

Authors:  William A Wolf; Gerald J Bieganski; Veronica Guillen; Laurence Mignon
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

9.  Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.

Authors:  Antony R Knight; Anil Misra; Kathleen Quirk; Karen Benwell; Dean Revell; Guy Kennett; Mike Bickerdike
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.